Although the survival rate of breast cancer patients has been increased by molecular targeted therapies against HER2 or hormone receptors1–3, TNBC is associated with the worst prognosis4, and TNBC patients show relapse and frequently develop metastasis in visceral organs. This evidence concerns the gene ERBB2 and breast carcinoma.